Study shows GSK’s novel diabetes treatment Syncria® (albiglutide) improves glucose control and reduces weight

New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria® (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing.